High expression of microRNA 221 is a poor predictor for glioma

Yanlin Song, MD\textsuperscript{a,b}, Min He, MD\textsuperscript{c}, Jing Zhang, MD\textsuperscript{a}, Jianguo Xu, MD, PhD\textsuperscript{a,*}

**Abstract**

**Background:** MicroRNA 221 has been found to be a good marker for several cancers. Some studies also focused on the relationship between microRNA 221 and glioma. However, the results are controversial. We aimed to systematically evaluate the prognostic role of microRNA 221 in glioma through performing a meta-analysis.

**Methods:** The articles which were included in our study were searched on the Web of Science, EMBASE, PubMed, Cochrane Library and China National Knowledge Infrastructure. The basic characteristics and relevant data were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic role of microRNA 221 in glioma.

**Results:** Eight studies with 1069 patients were included. We systematically evaluated the role of microRNA 221 for overall survival (OS) and disease free survival (DFS) in glioma patients (HR for OS = 1.66, 95% CI, 1.34–2.04; HR for DFS = 1.14, 95% CI, 1.02–1.26). Subgroup analyses were performed according to the nation of the studies, the origin of the samples, the stage of the tumors, the cutoff value, and the method for detecting the microRNA 221. No significant publication bias was found ($P_f = .133$).

**Conclusion:** In conclusion, high expression of microRNA 221 was related to poor prognosis of glioma. These findings may assist future exploration on microRNA 221 and help predict the prognosis of glioma. However, due to the significant heterogeneity of these studies, more studies are warranted.

**Abbreviations:** CI = confidence interval, DFS = disease free survival, HR = hazard ratio, OS = overall survival, PRISMA = preferred reporting items for systematic review and meta-analysis, Q-PCR = quantitative polymerase chain reaction, SE = stand error.

**Keywords:** glioma, microRNA 221, prognosis, survival

---

1. **Introduction**

Glioma is still the most common and malignant tumor in central nervous system (CNS) for now\textsuperscript{[1,2]}. The high morbidity and mortality of glioma has promoted the progression of the treatment of glioma in last decade\textsuperscript{[3]}. Although the median survival time of glioma was longer than before, 5-year survival rate was <10%\textsuperscript{[4]}. Finding a novel biomarker is important for improving the outcome of glioma patients.

MicroRNAs which were identified in 1990s were related to the regulation of gene expression\textsuperscript{[5]} and the regulation processes always occur on post-transcriptional level. Sometimes, the regulation might lead to the translation inhibition or mRNA degradation by combining with targeted mRNA\textsuperscript{[6,7]}. It has been proved that MicroRNAs play an important role on cell proliferation, apoptosis, differentiation, and metabolism\textsuperscript{[8–10]}. And the aberrant expression of microRNAs always occurs in the tumor\textsuperscript{[11]}. Given that microRNAs are much conserved small non-coding RNA, it can be a good predictor for the prognosis of the tumor patients. It has been reported that microRNA 133, 210, 310, 155, and 650 are good markers for the prediction of the prognosis of glioma.

MicroRNA 221 was proved to be related to the survival, growth, invasion, and malignant of glioma cells by previous studies\textsuperscript{[12–17]}. It has been found that high expression of microRNA 221 is associated to the poor prognosis of liver cancer, colorectal cancer, and ovarian cancer\textsuperscript{[18–20]}. Some clinical
research has demonstrated the prognostic role of microRNA 221 in glioma. However, the results of these studies are controversial. In order to reach a consensus, we systematically evaluated the prognostic role of microRNA in glioma.

2. Method

2.1. Search strategy

We designed, conducted, and reported the study based on the preferred reporting items for systematic review and meta-analysis (PRISMA) statement. And the data were analyzed according to the Cochrane Handbook. We developed the article by the order of guidelines of system reviews. Since this is a meta-analysis, ethical approval was not necessary.

The articles which were used in our study were searched (to November 24, 2019) on the Web of Science, EMBASE, PubMed, Cochrane Library, and China National Knowledge Infrastructure. The keywords for searching were showed below: microRNA 221 (microRNA 221-3p or lsa-miR-221), glioma (astrocytoma or glioblastoma or ependymoma or subependymal or ganglioglioma or gliosarcoma or medulloblastoma or oligodendroglioma), prognosis. Boolean operators (AND/OR) were used to combine these keywords and their synonyms or Medical Subject Headings.

2.2. Study selection

The articles were screened by JZ and YS independently. And the articles which were found before were managed by EndNote 8. Firstly, we screened the articles by the title and abstract. Then the potential articles were carefully read in full text. The inclusion criteria included: the patients were diagnosed with glioma and the diagnosis was verified by histopathological examination; the expression of microRNA221 was measured; the patients were followed up for overall survival or disease free survival. Enough data were reported in the article to estimate the prognostic role of microRNA221 for glioma. The articles which did not have enough data, case reports, reviews, letters, and conference abstract were excluded.

2.3. Data extraction

The relevant data in eligible articles were extracted by JZ and YS independently. The hazard ratio (HR) with 95% confidence interval (CI) were extracted firstly. Besides, the related data which can calculate the HR and 95% CI were extracted too. The following information was also extracted from each article: the name of first author, year of publication, name of the investigated sample, the methods for testing microRNA, cut-off of microRNA, the nation of the study, type of samples, number of samples, the methods for testing microRNA, cut off of microRNA221 and the characteristics of patients (sex, age, and stage).

2.4. Study quality assessment

The Newcastle Ottawa Scale (NOS) was used for assessing the quality of the included studies. The scale assessed 3 aspects of these studies, including selection, comparability and outcome, and each item was assigned 1 to 2 points. So the maximum score for a given study was 9 points. In this article, studies with score of 7 points or >7 points were considered to be a high quality study.

2.5. Statistical analysis

The Log[HR] and stand error (SE) were calculated from the HR and 95% CI. If HR was not showed in the article, we could get the data by the method of Troiano et al. Then all calculated data were used for the construction of forest plots which is used to estimate the pooled prognostic role of microRNA221 in glioma patients. The P value <.05 was considered to be significant. Besides, the 95% CI cannot overlap 1. The Higgins Index (I^2) was calculated to assess the heterogeneity of these studies. I^2 >50% and OR or P value <.1 was considered to be significant. The data were investigated with random-effect models no matter the heterogeneity was significant or not. If the heterogeneity was significant, we performed sensitivity analysis of these studies which can figure out the contribution of each article in the heterogeneity. Sub-group analysis was used to learn about the contribution of the nation of the studies, the origin of the samples, the stage of the tumors, the cut-off value, and the method for detecting the microRNA 221. At last, publication bias was assessed by Begg funnel plots. All analysis was conducted by STATA 11.0 (College Station, TX, StataCorp.)

3. Results

3.1. Study research

At the beginning, 81 articles were found in the first round research. And no duplicates were found in these articles. Then 70 articles were excluded after screened by the titles and abstracts. The rest 11 articles were further filtered by full-text reading. After step by step screening, only 8 articles which met the inclusion criteria were retained. The process of study screening was showed in the Fig. 1.

3.2. Study characteristics

Among the 8 articles, 7 articles analyzed HR for the overall survival while only one article analyzed HR for progression-free survival. The basic characteristics were extracted from these articles. As shown in Tables 1 and 2, these studies were conducted from 2011 to 2018 in 2 different countries. A total of 1069 patients were involved in the study. The samples were isolated from tumor or blood. Quantitative polymerase chain reaction (Q-PCR) was used to test most samples. Only one study evaluated the expression of microRNA 221 by immunohistochemistry scoring. Three articles only studied the relationship between microRNA 221 and prognosis in stage IV glioma patients, and other articles investigated patients in all stages. And the cut-off value included mean, median, and 60%.

3.3. Overall analysis

In 8 included articles, 10 data sets were used to analyze the prognostic role of microRNA 221 for glioma patients (Fig. 2). Among these data, 7 data sets were used to analyze the role of microRNA221 on OS and 3 data sets were used to analyze the role on disease free survival (DFS). The pooled HR of higher microRNA 221 for overall survival (OS) was 1.66 (95% CI, 1.34–2.04) and the HR for DFS was 1.14 (95% CI, 1.02–1.26). The heterogeneity was evaluated for OS (I^2 =50.2%, P =.062) and DFS (I^2 =0%, P =.663). Next we learned about the contribution of each article
on heterogeneity of OS. After excluding the article by RZ, CZ, SS separately, \(I^2\) shrank to 39.10%, 47.20%, 5.50%. So we believed that the study by SS was the major resource of the OS heterogeneity. So we analyzed the HR after excluding this study. The pooled HR changed to 1.75 (95% CI, 1.45–2.1), which was still significant.

### Table 1  
Characteristics of the included articles.

| Author    | Year | Country | Sample | Number | Stage | Histological classification | Quality score (NOS) |
|-----------|------|---------|--------|--------|-------|-----------------------------|---------------------|
| Chen Y    | 2018 | China   | Tissue | 114    | IV    | Glioblastoma                | 9                   |
| Sun C     | 2017 | USA     | Tissue | 548    | IV    | Glioblastoma                | 8                   |
| Xue L     | 2017 | China   | Tissue | 165    | I-IV  | Glioma                      | 8                   |
| Li X      | 2016 | China   | Tissue | 45     | I-IV  | Glioma                      | 8                   |
| Zhang R   | 2016 | China   | Blood  | 50     | I-IV  | Glioma                      | 8                   |
| Zhang C   | 2012 | China   | Tissue | 36     | I-IV  | Glioma                      | 8                   |
| Srinivasan S | 2011 | USA     | Tissue | 111    | IV    | Glioblastoma                | 7                   |
| Chen W    | 2016 | USA     | Tissue | 69     | IV    | Glioblastoma                | 7                   |
|           |      |         |        | 102    | IV    | Glioblastoma                | 7                   |
|           |      |         |        | 109    | IV    | Glioblastoma                | 7                   |

NOS = Newcastle Ottawa Scale.

### 3.4. Subgroup analysis

We also analyzed the effects of other factors, like nation of study, type of study, the origin of the samples, the stage of the tumors, the cut-off value, and the method for detecting the microRNA 221 on the HR of OS (Table 3). Among 7 data sets, 2 were from the United States and 5 were from China. The pooled HR in
China studies was 2.03 (95% CI, 1.58–2.60). And the pooled HR in USA was also significant (HR = 1.32 95% CI, 1.16–1.49). Then we calculated the HR of different samples. Only one study detected the microRNA in blood. So we analyzed the HR by excluding this study. After excluding this study, the HR changed to 1.54 (95% CI, 1.27–1.87). Next, we analyzed the HR in different stages of glioma. The pooled HRs in stage IV and stage I-IV studies were 1.38 (95% CI, 1.15–1.66) and 2.01 (95% CI, 1.54–2.64), respectively. After that, the HRs of different cut-off values were calculated. The expression of microRNA 221 was divided into high and low degree by different cut-off values. Among these studies, 3 studies defined the median value as the cut-off point, one study defined the mean value as the cut-off point, and one study defined 60% as the cut-off value. The rest 2 studies did not show the definite cut-off value in the article. We divided them into non-median cut-off value group along with the studies of mean cut-off value and 60% cut-off value. The pooled HR of this group was still significant (HR = 1.80 95% CI, 1.20–2.69) which reached a same conclusion with the median cut-off group (HR = 1.60 95% CI, 1.27–2.00). At last, the HR of different methods for detecting the microRNA 221 was analyzed. We calculated the HR by excluding the study which used immunohistochemistry to score the level of microRNA 221 (HR = 1.60, 95% CI, 1.30–1.94).

Overall, the factors mentioned above did not change the conclusion that microRNA 221 was a potential marker for the prognosis of glioma patients.

3.5. Publication bias

We showed the publication bias by funnel plot. And we analyzed the publication bias by Begg test. As shown in Fig. 3, no significant bias was found in this study (P = .133).

4. Discussion

In this article, we analyzed the pooled HR from the selected studies (HR for OS = 1.66, 95% CI, 1.34–2.04; HR for DFS = 1.14, 95% CI, 1.02–1.26). Besides, we also analyzed the influence of the nation of the study, the origin of the samples, the stage of the tumors, the cut-off value, and the method for detecting the microRNA 221 for HR of OS (Table 2). Not surprisingly, these factors did not influence our conclusion that microRNA 221 was related to the prognosis of glioma. In order to find out the major resource of heterogeneity, the sensitivity analysis was performed. We calculated the I² by excluding each study which were included in our research. After excluding the article by SS, I² shrank to 5.50%. So we believed that the study by SS was the major resource of heterogeneity. The different cut-off value (60%) might be the reason for the heterogeneity in the context of our included information. In addition, other information not included in the article might also be a reason for the significant heterogeneity, including different treating strategies and follow-up time. The pooled HR was still significant for OS after excluding this article (HR = 1.75, 95% CI, 1.45–2.1). Before this study, many kinds of microRNAs (like microRNA 630, microRNA 320, microRNA 155, microRNA 210, and microRNA 133) had been proved to be related to the prognosis of glioma.[12,4,31–43] And microRNA 221 had been identified to be a good marker of liver cancer, colorectal cancer, and ovarian cancer.[18–20] Since a lot of studies had investigated the role of microRNA 221 on proliferation, invasion and angiogenesis of glioma cells, numerous articles were published to verify the relationship between microRNA 221 and glioma.[12–47] However, different conclusions were drawn from these studies. So our study systematically analyzed the effects of microRNA 221 and further supported the role microRNA 221 on the prognosis of glioma.

Previous research has shown that high expression of microRNA 221 increased the ability of proliferation, invasiveness, and migration of glioma cells, which might partially explain the relationship between microRNA 221 and the short survival of glioma patients.[12,4,34,35] The study performed by Zhang et al.[45] showed that the suppression of microRNA 221 resulted in the down-regulation of G1 to S shift through the up-regulation of p27 in vivo and in vitro. Another study by Cai et al.[44] also proved the effects of microRNA 221 on the proliferation of glioma cells. The study also confirmed that high expression of microRNA 221 promoted the migration and invasion of glioma cells via targeting SEMA3B. The same conclusion was also drawn from the research of Zhang et al.[45] and Quintavalle et al.[16] But different mechanisms were suggested. It was confirmed that microRNA 221 was associated with the resistance of chemotherapy and radiotherapy.[136–39] And the resistances were both related to the activation of AKT. The resistance of chemotherapy (carmustine) was related to the down-regulation of phosphatase and tensin homolog deleted on chromosome ten status.[37,39] High expression of microRNA 221 also induced the resistance of temozolomide by targeting DNM3 genes.[36]

Glioma is a heterogeneous disease which arises from brain parenchyma.[42] High grade glioma always means high mortality and poor prognosis. Many kinds of biomarker has been proved

| Author  | Year | Cut-off | Methods | Results | HR   | 95% CI         | P value |
|---------|------|---------|---------|---------|------|---------------|---------|
| Chen Y  | 2018 | None    | Q-PCR   | OS      | 2.112| 1.125–3.9651  | .02     |
| Sun C   | 2017 | Median  | Q-PCR   | OS      | 1.456| 1.135–1.8731  | .0031   |
| Xue L   | 2017 | Median  | Q-PCR   | OS      | 1.656| 1.135–2.486   | .0089   |
| Li X    | 2016 | Mean    | Q-PCR   | OS      | 2.18 | 1.02–4.65     | .044    |
| Zhang R | 2016 | None    | Q-PCR   | OS      | 2.4  | 1.42–4.05     | .0011   |
| Zhang C | 2012 | Median  | IHC     | OS      | 2.63 | 1.25–5.56     | .011    |
| Srinivasan S | 2011 | 60%    | Q-PCR   | OS      | 1.27 | 1.068–1.4706  | .0014   |
| Chen W  | 2016 | Median  | Q-PCR   | DFS     | 1.25 | 0.98–1.6      | .77     |
|         |      | Median  | Q-PCR   | DFS     | 1.13 | 0.96–1.52     | .14     |
|         |      | Median  | Q-PCR   | DFS     | 1.09 | 0.93–1.3      | .26     |

CI = confidence interval; HR = hazard ratio; Q-PCR = quantitative polymerase chain reaction.
Apart from the expression of chondroitin sulfate, inflammation factors, matrix metallopeptidase 2, and matrix metallopeptidase 9, microRNAs have been verified to be good markers for the prognosis of glioma recently.\(^{[40–42]}\) Unlike the other factors mentioned before, microRNAs is a group of factors which can provide more evidence for the prognosis of glioma. More predictors of microRNAs means more evidence for the prognosis of glioma.
However, there are still some limitations in our study. Firstly, the origin of the sample was mostly from tumor tissue. But the microRNA 221 in blood has even greater potential for glioma patients as for the non-invasive detection. So more studies were needed to further evaluate the prognostic role of microRNA 221 in blood for glioma. Besides, a significant change occurred in the classification of glioma patients since 2016.[22] Both molecular parameters and histology were considered in the diagnosis on the 2016 World Health Organization (WHO) classification of CNS tumors while the previous classification only considered the histology. But the included studies did not distinguish the different molecular parameters of glioma patients. So more studies based on 2016 WHO classification of CNS tumors are warranted in the future.

In conclusion, our study proved that high expression of microRNA 221 is associated to the poor prognosis of glioma. These findings may assist future exploration on microRNA 221 and help predict prognosis of glioma. However, due to the significant heterogeneity between the studies, more studies are warranted.

### Author contributions

Conceptualization: Yanlin Song, Min He, Jing Zhang, Jianguo Xu.  
Data curation: Yanlin song, Min He, Jing Zhang.  
Formal analysis: Yanlin Song, Min He.  
Methodology: Yanlin song, Min He.  
Project administration: Yanlin Song, Jianguo Xu.  
Supervision: Jianguo Xu.  
Writing – original draft: Yanlin Song, Min He, Jing Zhang.  
Writing – review & editing: Jianguo Xu.

### References

[1] Jones DTW, Bandopadhayay P, Jabado N. The power of human cancer genetics as revealed by low-grade gliomas. Annu Rev Genet 2019;53:483–303.  
[2] Lv QL, Du H, Liu YL, et al. Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. Oncol Rep 2017;38:959–66.
[3] Ouyang Q, Gong X, Xiao H, et al. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. Mol Cancer 2015;14:21.

[4] Xue K, Yang J, Hu J, et al. MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma. Artif Cells Nanomed Biotechnol 2018;46:815–8.

[5] Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012;4:143–59.

[6] Lu TX, Rothenberg ME. MicroRNA. J Allerg Clin Immunol 2018;141:39–52.

[7] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597–610.

[8] Vienberg S, Geiger J, Madsen S, et al. MicroRNAs in metabolism. Acta Physiol (Oxf) 2017;219:346–61.

[9] Zhang ZW, Li H, Chen SS, et al. MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes. Braz J Med Biol Res 2017;50:e5760.

[10] Morgado AL, Rodrigues CM, Sola S. MicroRNA-145 regulates neural stem cell differentiation through the Sox2-Lin28/let-7 signaling pathway. Stem Cells 2016;34:1386–95.

[11] Lee YS, Datta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199–227.

[12] Zhang J, Han L, Ge Y, et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 2010;36:913–20.

[13] Zhang C, Zhang JX, Zhang AL, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010;9:229.

[14] Zhang C, Zhang J, Hao J, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 2012;10:119.

[15] Yang F, Wang W, Zhou C, et al. MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. Tumour Biol 2015;36:5763–73.

[16] Quintavalle V, Garofalo M, Zanca C, et al. MiR-221/222 overexpression in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012;31:858–68.

[17] Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008;68:2773–80.

[18] Yau TO, Wu CW, Dong Y, et al. microRNA-221 and microRNA-18a identification in stol as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer 2014;111:1765–71.

[19] Shaker O, Alhelf M, Morcos G, Elsharkawy A. miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infect Genet Evol 2017;51:173–81.

[20] Hong F, Li Y, Xu Y, et al. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res 2013;41:64–71.

[21] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[22] Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018;21:579–87.

[23] Troiano G, Mastrangelo F, Caponio VCA, et al. Predictive prognostic value of tissue-based microrna expression in oral squamous cell carcinoma: a systematic review and meta-analysis. J Dent Res 2018;97:759–66.

[24] Zhang R, Pang B, Xin T, et al. Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol Neurobiol 2016;53:1452–60.

[25] Xue L, Wang Y, Yue S, et al. The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis. Neurol Sci 2017;38:67–73.

[26] Sun C, Zhao X. Joint covariate detection on expression profiles for selecting prognostic miRNAs in glioblastoma. Biomed Res Int 2017;2017:3017948.

[27] Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17458.

[28] Li X, Zheng J, Chen L, et al. Predictive and prognostic roles of abnormal expression of tissue miR-125b, miR-221, and miR-222 in glioma. Mol Neurobiol 2016;53:577–85.

[29] Chen W, Yu Q, Chen B, et al. The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients. Oncotarget 2016;7:53392–413.

[30] Chen YY, Ho HL, Lin SC, et al. Upregulation of miR-125b, miR-181d, and miR-221 predicts poor prognosis in MGMT promoter-unmethylated glioblastoma patients. Am J Clin Pathol 2018;149:412–7.

[31] Sun B, Pu B, Chu D, et al. MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neurooncol 2013;115:375–80.

[32] Sun J, Shi H, Lai N, et al. Overexpression of microRNA-153 predicts poor prognosis in glioma patients. Med Oncol 2014;31:911.

[33] Lai NS, Wu DG, Fang XG, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 2015;112:1241–6.

[34] Cai G, Qiao S, Chen K. Suppression of miR-221 inhibits glioma cells proliferation and invasion via targeting Sema3b. J Neurooncol 2013;115:371–80.

[35] Zhang C, Kang C, You Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 2009;34:1633–60.

[36] Yang JK, Yang JP, Tong J, et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. Brain Res 2014;1551:55–65.

[37] Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17458.

[38] Li W, Guo F, Wang P, et al. Zhang C. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med 2014;14:183–95.

[39] Chen L, Zhang J, Han L, et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep 2012;27:834–40.

[40] Zhou W, Yu X, Sun S, et al. Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence. Biomed Pharmacother 2014;11:8109.

[41] Tsidulko AY, Kazanskaya GM, Volkov AM, et al. Chondroitin sulfate content and decorin expression in glioblastoma are associated with proliferative activity of glioma cells and disease prognosis. Cell Tissue Res 2019;379:147–55.

[42] Feng Y, Wang J, Tan D, et al. Relationship between circulating inflammatory factors and glioma risk and prognosis: a meta-analysis. Cancer Med 2019;8:7454–68.